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Abstract
Background: Multiple myeloma (MM) is a clonal plasma cell malignancy associated with osteolytic bone disease.
Recently, the role of MM-derived exosomes in the osteoclastogenesis has been demonstrated although the
underlying mechanism is still unknown. Since exosomes-derived epidermal growth factor receptor ligands (EGFR)
are involved in tumor-associated osteolysis, we hypothesize that the EGFR ligand amphiregulin (AREG) can be
delivered by MM-derived exosomes and participate in MM-induced osteoclastogenesis.
Methods: Exosomes were isolated from the conditioned medium of MM1.S cell line and from bone marrow (BM)
plasma samples of MM patients. The murine cell line RAW264.7 and primary human CD14+ cells were used as
osteoclast (OC) sources.
Results: We found that AREG was specifically enriched in exosomes from MM samples and that exosomes-derived
AREG led to the activation of EGFR in pre-OC, as showed by the increase of mRNA expression of its downstream
SNAIL in both RAW264.7 and CD14+ cells. The presence of neutralizing anti-AREG monoclonal antibody (mAb)
reverted this effect. Consequently, we showed that the effect of MM-derived exosomes on osteoclast differentiation
was inhibited by the pre-treatment of exosomes with anti-AREG mAb. In addition, we demonstrated the ability of
MM-derived AREG-enriched exosomes to be internalized into human mesenchymal stromal cells (MSCs) blocking
osteoblast (OB) differentiation, increasing MM cell adhesion and the release of the pro-osteoclastogenic cytokine
interleukin-8 (IL8). Accordingly, anti-AREG mAb inhibited the release of IL8 by MSCs suggesting that both direct and
indirect effects are responsible for AREG-enriched exosomes involvement on MM-induced osteoclastogenesis.
Conclusions: In conclusion, our data indicate that AREG is packed into MM-derived exosomes and implicated in
OC differentiation through an indirect mechanism mediated by OBs.
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Background
Multiple myeloma (MM) is a clonal plasma cell (PC)
malignancy characterized by the abnormal accumulation
of malignant MM cells within the bone marrow (BM)
which leads to osteolytic bone disease [1, 2]. Active MM
is characterized by severe imbalance between osteoclasts
(OCs), responsible for bone resorption and osteoblasts
(OBs), responsible for bone formation [3]. The increased
OC activity promotes the progression of MM, allowing
the establishment of a loop between bone destruction
and the survival of cancer cells [4].
MM cells stimulate OC differentiation mainly indir-
ectly stimulating the production, by the surrounding
cells, of soluble factors [5] such as the receptor activator
of nuclear factor kappa-Β ligand (RANKL). Other cyto-
kines produced directly by MM cells and their micro-
environment as interleukins (ILs) IL-1β, IL-3, and IL-6
are also involved in MM-induced osteoclastogenesis [6].
The increased osteolytic activity induced by MM cells is
strictly associated with the inhibition of OB differenti-
ation in human mesenchymal stromal cells (MSCs),
resulting in a marked alteration of bone remodeling. In
MM, the presence of cytokines and the physical inter-
action between MSCs and MM cells impaired bone for-
mation by inhibiting osteogenic precursors and
stimulated the production of osteoclastogenic cytokines
that support OC formation. [7, 8].
In recent years, several studies have been focused on
the possible role of exosomes, nanosize lipoproteic
structures that have been recognized as a new mechan-
ism of cell-to-cell communication. This feature is attrib-
uted to their ability to actively transport mRNA,
miRNA, proteins, and growth factors towards target
cells, modifying their behavior as well as the microenvir-
onment [9, 10].
Emerging evidence highlighted the role of exosomes in
several cancer types including MM; cell-derived extracel-
lular vesicles are in fact considered regulators of MM
BM microenvironment and are able to promote MM
progression in a paracrine and autocrine manner [11–
15]. Furthermore, our previous data have shown that
MM cell-derived exosomes play a relevant functional
role in OC differentiation [16]. In particular, we found
that exosome treatment increased the expression of
OC-specific markers, such as tartrate-resistant acid
phosphatase (TRAP), cathepsin K (CTSK), and matrix
metallopeptidase 9 (MMP9) and directly control OC for-
mation and activity. These results highlight the ability of
exosomes to affect directly OC differentiation and func-
tion. Here, we focus on defining how MM cell-derived
exosomes act on osteoclastogenesis.
The epidermal growth factor receptor (EGFR) is a
transmembrane glycoprotein with intrinsic tyrosine kin-
ase activity that can be bound and activated by a family
of seven peptide growth factors including amphiregulin
(AREG). The EGFR system acts in various cellular
physiological and pathological processes such as prolifer-
ation, differentiation, and motility. Recent studies have
reported that this signaling network plays an essential
role in bone metabolism by affecting both OBs and OCs
[17]. Further studies have revealed that EGFR ligands
are able to stimulate OC formation by decreasing in
OBs the expression of OPG [18]. In addition to the
EGFR system, IL8, a cytokine well studied for its role in
promoting tumor angiogenesis, cell motility, and inva-
sion [19], has been described as an activator of bone de-
struction in metastatic and MM bone disease [20, 21].
Here, we investigated whether MM exosomes, from
both cell lines and MM patients, affect OC differenti-
ation by activating the EGFR pathway.
Methods
Data set analysis
The expression of AREG at mRNA level on PCs from 11
monoclonal gammopathy of undetermined significance,
133 MM patients at the diagnosis, 9 primary plasma cell
leukemia (PCL), and 4 healthy donors (GSE16122) [22],
generated on AffymetrixGeneChip HG-U133A arrays
(Affymetrix, Santa Clara, CA, USA), were extracted from
CEL files using RMA normalization procedure and cus-
tom CDF annotation package (GeneAnnot v2.2.1, Reho-
vot, Israel), as previously described [23].
Reagents
Recombinant AREG (R&D Systems, Abingdon, UK) was
reconstituted at 0.1 mg/ml in sterile PBS, aliquoted and
stored at − 20 °C. Neutralizing anti-AREG mAb (R&D
Systems, Abingdon, UK) was reconstituted at 0.2 mg/ml
in sterile PBS, aliquoted and stored at − 20 °C. SB225002
(Cayman Chemical, MI, USA) was solubilized at 10 mM
stock solution in DMSO and stored at 20 °C.
Cells and cell culture conditions
Cell lines
The human myeloma cell line (HMCL) MM1.S was pur-
chased from Leibniz Institute Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH (Braun-
schweig, Germany). Cells were maintained in RPMI-1640
medium supplemented with 10% fetal bovine serum
(FBS), L-glutamine (2mM), and antibiotics (100U/ml
penicillin and 100 μg/ml streptomycin), all obtained from
ThermoFisher Scientific (Waltham, MA, USA).
Murine macrophage RAW 264.7 cells were purchased
from ATCC (Manassas, VA, USA). Cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% FBS, 2 mM L-glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin (Euroclone,
Milan, Italy) and differentiated to OC as previously
Raimondo et al. Journal of Hematology & Oncology            (2019) 12:2 Page 2 of 15
described [24]. The human telomerase reverse tran-
scriptase transduced mesenchymal stromal cell line
(hTERT-MSCs) was kindly gifted by Dr. Giuseppe Gaipa
(Monza, Italy). hTERT-MSCs were cultured in mesen-
chymal stem cell growth medium (MSCGM™ Bullet Kit,
Lonza, Walkersville, MD, USA) to maintain them into
an undifferentiated condition and in Mesenchymal Stem
Cell Osteogenic Differentiation Medium to induce
osteogenic differentiation (MSC Osteogenic Differenti-
ation BulletKit™, Lonza).
CD14+ monocytes isolation
Human peripheral mononuclear cells (PBMCs) were iso-
lated by Ficoll-Paque (GE Helthcare-Bio Science, Upp-
sala, Sweden) from whole blood of the healthy donors in
accordance with the Declaration of Helsinki guidelines
and University of Palermo Ethics committee. Once iso-
lated, cells were washed with MACS isolation buffer for
monocyte isolation. PBMCs were then incubated with
human CD14 microbeads (MiltenyiBiotec, BergischGlad-
bach, Germany) for 15 min at 4 °C. The magnetic separ-
ation was performed using LS columns (MiltenyiBiotec),
and the bound cells were then washed and suspended in
complete medium for further experiments.
Exosome isolation
Exosomes released by MM1.S after a 48h culture period
in presence of FBS previously ultracentrifuged (exo-
some-free FBS) were isolated from conditioned culture
medium by differential centrifugation, as previously de-
scribed [25]. Briefly, culture medium was centrifuged
subsequently for 5 min at 300×g, 15 min at 3000×g, and
30min at 10,000×g and ultracentrifuged 90 min at
100,000×g in a Type 70 Ti, fixed angle rotor.
Exosomes were isolated from bone marrow (BM)
plasma of four MM patients (three newly diagnosed and
one relapsed). All patients provided written informed
consent in accordance with the Declaration of Helsinki.
The Institutional Review Board of the University of
Parma (Italy) approved this part of the study. Exosomes
were isolated from human plasma and prepared as de-
scribed above. Exosome pellets were washed and sus-
pended in PBS, and exosome protein content was
determined by the Bradford assay.
Cell treatment
Exosomes (50 μg/ml) previously isolated from either
MM1.S or BM plasma MM samples were treated or not
with anti-AREG mAb (50 μg/ml) for 2 h at 37 °C. Both
human primary CD14+ monocytes and RAW 264.7 cells
were incubated for 3 and 6 days in osteoclastogenic
medium (recombinant human (rh) RANKL 25 ng/ml
and MCSF 25 ng/ml), with exosomes treated or not with
anti-AREG mAb and with rhAREG (50 μg/ml). The
media were changed every 3 days. At the end of the cul-
ture period, OC differentiation and EGFR activation
were assessed as described below. Human primary
CD14+ monocytes purified from PB were also treated
with rh IL8 and with the conditioned medium of
hTERT-MSCs treated with MM1.S exosomes in the
presence or not of CXCR1-CXCR2 inhibitor (SB225002).
At the end of the culture period, OC differentiation was
assessed.
OB differentiation
Lastly, in other experimental setting, hTERT-MSCs were
used to evaluate the role of MM exosomes on OB differ-
entiation. hTERT-MSCs were treated for 10 and 14 days
with exosomes from MM1.S or from MM plasma pa-
tients in undifferentiating or osteogenic differentiation
medium; the media were changed every 3 days. At the
end of the culture period, osteogenic differentiation,
exosome uptake, and EGFR activation were assessed.
OC differentiation
OC differentiation of human PB CD14+ were evaluated
after 10 days of culture conditions by the detection of
tartrate-resistant acid phosphatase (TRAP) activity, ac-
cording to the manufacturer’s protocol (Acid Phosphat-
ase, Leukocyte (TRAP) Kit; Sigma–Aldrich, USA) and
evaluated by light microscopy. Three independent exper-
iments were performed in triplicate; cells from five dif-
ferent fields were counted for each condition.
Atomic force microscopy
Fresh cleaved mica was incubated with a vesicle solution
diluted in PBS to a final concentration of 30 ng/μl for
15 min at room temperature. Sample was gently rinsed
by PBS, and tapping mode atomic force microscopy
(AFM) measurements were carried out in liquid by using
a Nanowizard III scanning probe microscope (JPK In-
struments AG, Germany) equipped with a 15-μm scan-
ner, and AC40 (Bruker) silicon cantilevers (nominal
spring constant 0.1 N/m, typical tip radius 10 nm, reson-
ance frequency 55 kHz, scan rate 1.5 Hz, free oscillation
amplitude 7 nm).
Dynamic light scatter
Exosome size distribution was determined by dynamic
light scattering (DLS) experiments. Collected
MM-exosome patient samples were diluted to avoid
inter-particle interaction and placed at 20 °C in a
thermostatic cell compartment of a Brookhaven Instru-
ments BI200-SM goniometer, equipped with a Brookha-
ven BI-9000 correlator and a solid-state laser tuned at
532 nm. Scattered intensity autocorrelation functions
were analyzed by using a constrained regularization
method or alternatively a gamma distribution [16, 26] in
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order to determine the size distribution (namely the
z-averaged hydrodynamic diameter distribution).
Uptake of MM-derived exosomes by hTERT-MSCs
MM1.S exosomes were labeled with PKH26 Red Fluor-
escent Cell Linker Kits (Sigma–Aldrich, USA) according
to the supplier’s information. Specifically, exosomes col-
lected after the 100,000×g ultracentrifugation were incu-
bated with PKH26 dye, previously diluted in the diluent
C solution, for 10 min at room temperature. Labeled
exosomes were washed in PBS by ultracentrifugation;
the pellets were suspended in low serum medium and
incubated with hTERT-MSCs for 3 h. hTERT-MSCs were
grown on coverslips coated with COL1A1 (Calbiochem,
Darmstadt, Germany) and were treated with 50 μg/ml of
exosomes pre-treated or not with anti AREG mAb.
hTERT-MSCs were stained with Actin Green (Molecular
Probes, Life Technologies, Carlsbad, CA, USA) that
binds actin with high affinity. Nuclei were stained with
Hoechst (Molecular Probes, Life Technologies, Carlsbad,
CA, USA) and analyzed by confocal microscopy. Fluor-
escence intensity was measured using IMAGE J software
(https://imagej.nih.gov/ij//).
Adhesion assay
Adhesion assay was performed as previously described
by our group [27]. Briefly, hTERT-MSCs monolayer was
incubated for 48 h with 50 μg/ml of MM1.S exosomes
pre-treated or not with anti AREG mAb. After treat-
ments, cells were washed with PBS and MM1.S cells
were added for 3.5 h at 37 °C. Adherent cells were
stained with hematoxylin/eosin, and each test group was
assayed in triplicate; five high-power (400×) fields were
counted for each condition.
Osteolmage bone mineralization assay
The amount of in vitro mineralization of hTERT-MSCs,
seeded in 96-well tissue culture plates and treated for 10
and 14 days with exosomes from MM1.S cells in undif-
ferentiating medium or in osteogenic differentiation
medium, was evaluated using the Osteolmage
Mineralization Assay Kit (Lonza, Walkersville, MD,
USA), according to the supplier’s information. Briefly,
after each culture time point, media was removed; cells
were washed in PBS and fixed. After fixation, cells were
washed in the appropriate buffer and the staining re-
agent added. Mineralization was quantitated on a fluor-
escent plate reader at a 492/520 nm ratio.
Flow cytometry
Phosphorylation levels of EGFR in hTERT-MSCs incu-
bated for 48 h with 50 μg/ml of MM1.S exosomes
pre-treated or not with anti AREG mAb were deter-
mined by flow cytometry. Cells were fixed and
permeabilized with Leucoperm kit (AbDSerotec). EGFR-
or phospho-EGFR unconjugated primary antibody (Cell
Signalling Technology, Lane Danvers, MA, USA) was
added; cells were washed, and a FITC secondary anti-
body was added. Stained cells were analyzed on a FACS
Calibur (Becton Dickinson) using Cellquest software.
Western blot assay
Total proteins from MM1.S cells lysates, MM1.S exo-
some, conditioned medium of cells deprived of exo-
somes, patient’s exosomes, and RAW 264.7 lysates were
extracted and analyzed by SDS-PAGE followed by west-
ern blotting. Antibodies used in the experiments were as
follows: anti-EGFR, pEGFR (Cell Signalling Technology,
Lane Danvers, MA, USA), anti-AREG (Novus Biologi-
cals), and anti-GAPDH (Santa Cruz Biotechnology, CA,
USA).
RNA extraction and real-time PCR
RNA was extracted using the commercially available
IllustraRNAspin Mini Isolation Kit (GE Healthcare, Lit-
tle Chalfont, Buckinghamshire, UK), according to the
manufacturer’s instructions. Total RNA was reverse
transcribed to cDNA using the High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems, Foster City,
CA, USA). RT-QPCR was performed in 48-well plates
using the Step-One Real-Time PCR system (Applied
Biosystems). For quantitative Sybergreen real-time PCR,
reaction was carried out in a total volume of 20 μl con-
taining 2× SYBR Green I Master Mix (Applied Biosys-
tems), 2 μl cDNA, and 300 nM forward and reverse
primers. Primer sequences, obtained from Invitrogen
(Foster City, CA, USA), were as follows:
Human GAPDH (5′-ATGGGGAAGGTGAAGGTCG-
3′, 5′-GGGTCATTGATGGCAACAATAT-3′)
Human SNAIL (5′-GCGAGCTGCAGGACTCTAAT-
3′, 5′-CCCGCAATGGTCCACAAAAC-3′)
Human MMP9 (5′-CGCTACCACCTCGAACTTTG-
3′, 5′-GCCATTCACGTCGTCCTTAT-3′)
Human TRAP (5′-GATCCTGGGTGCAGACTTCA-3′,
5′-GCGCTTGGAGATCTTAGAGT-3′)
Human CTSK (5′-ACCGGGGTATTGACTCTGAA-
3′, 5′-GAGGTCAGGCTTGCATCAAT-3′)
Human IL8 (5′-GAATGGGTTTGCTAGAATG
TGATA-3′, 5′-CAGACTAGGGTTGCCAGAT
TTAAC-3′)
Human ALP (5′-ACCGGGGTATTGACTCTGAA-3′,
5′-GAGGTCAGGCTTGCATCAAT-3′)
Human OCN (5′-GAGGGCAATAAGGTAGTGAA-3′,
5′-CATAGATGCGTTTGTAGGC-3′)
Human COL1A1 (5′-AAGGTGTTGTGCGATGACG
TG-3′, 5′-CACGTCATCGCACAACACCTT-3′)
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Human OPG (5′-GGCAACACAGCTCACAAGAA-3′,
5′-CTGGGTTTGCATGCCTTTAT-3′)
Mouse Gapdh (5′-CCCAGAAGACTGTGGATGG-3′,
5′-CAGATTGGGGGTAGGAACAC-3′)
Mouse Trap (5′-GCGACCATTGTTAGCCACA
TACG-3′, 5′-CGTTGATGTCGCACAGAGGGAT-3′)
Mouse Ctsk (5′-GCGTTGTTCTTATTCCGAGC-3′,
5′-CAGCAGAGGTGTGTACTATG-3′)
Mouse Mmp9 (5′-GCTGACTACGATAAGGACG
GCA-3′, 5′-GCGGCCCTCAAAGATGAACGG-3′)
Mouse Snail (5′-GCGAGCTGCAGGACTCTAAT-3′,
5′-CCCGCAATGGTCCACAAAAC-3′).
Human RANKL gene expression was assessed using
the TaqMan Gene Expression Assay (Life Technologies,
Milan, Italy).
Real-time PCR was performed in triplicates for each
data point. Relative changes in gene expression between
control and treated samples were determined using the
ΔΔCt method. Levels of the target transcript were nor-
malized to a GAPDH endogenous control, constantly
expressed in all samples (ΔCt). For ΔΔCt values, add-
itional subtractions were performed between treated
samples and control ΔCt values. Final values were
expressed as fold of induction.
ELISA assay
MMP-9 levels were quantified by Human MMP-9 ELISA
assays (Invitrogen) for CD14+ monocytes and with
mouse total MMP9–enzyme-linked immunosorbent as-
says (R&D Systems, Minneapolis, MN, USA) for RAW
264.7 cells according to the manufacturer’s protocol.
Furthermore, the levels of ALP and IL8 secreted by
hTERT-MSCs were quantified respectively by ALP
ELISA assay (Cloud-Clone Corp ELISA KIT assay,
Cloud-Clone Corp. Houston, TX, USA) and Human IL8
ELISA assay (R&D Systems, Minneapolis, MN) accord-
ing to the manufacturer’s protocol.
Statistical analysis
Data are expressed as means ± SD of three independent
experiments. Statistical analysis was done with
two-tailed unpaired t test using Graphpad Prism. Differ-
ences were considered significant when p ≤ 0.05.
Results
The EGFR ligand AREG is expressed by MM cells and
enriched in exosomes
By analyzing the mRNA expression level of EGFR li-
gands in a published dataset (accession number
GSE16122), we found that CD138+ cells expressed
AREG mRNA at variable levels among the different type
of monoclonal gammopathies (Fig. 1a). Consistently, we
found that HMCLs, as well as MM1.S-derived
exosomes, expressed AREG mRNA (Additional file 1:
Figure S1).
Exosomes were then isolated from one HMCL MM1.S
and characterized by the atomic force microscope
(AFM) in order to confirm that we are working with ves-
icles of about 80 nm (Fig. 1b). We found that AREG was
specifically enriched in exosomes as confirmed by its
low abundance in MM1.S cells and in the
exosomes-deprived conditioned medium (Fig. 1c).
MM1.S-exosomes induce the activation of EGRF pathway
in OC progenitor cells
We next investigated whether MM1.S-exosomes treat-
ment induced the activation of EGFR pathway in OC
progenitors. RAW 264.7 cells treated with MM1.S cell
line exosomes under osteoclastogenic conditions showed
an increase in the phosphorylation of EGFR (Fig. 2a).
The treatment with exosomes derived from MM1.S cells
pretreated with anti-AREG mAb reduces the phosphor-
ylation of EGFR. Subsequently, we found that the 6day
treatment with MM1.S-derived exosomes induced a sig-
nificant increase in the mRNA expression level of
SNAIL, a downstream target of EGFR, both in RAW
264.7 (Fig. 2b, upper panel) and in pre-osteoclast human
CD14+ (Fig. 2b, lower panel). The presence of
anti-AREG mAb reverted this effect (Fig. 2b).
AREG-enriched MM cell-derived exosomes induced OC
differentiation
Raimondi et al. demonstrated that MM-derived exo-
somes directly induce the expression of OC-specific
markers [16]. We confirmed that the treatment with
MM-derived exosomes from MM1.S increases
OC-specific markers, such as TRAP, CTSK, and MMP9
at mRNA level both in RAW 264.7 (Fig. 3a) and PB hu-
man CD14+ cells (Fig. 3b). This effect was confirmed at
protein level for MMP-9 (Fig. 3c) and by TRAP staining
(Fig. 3d). The pro-osteoclastogenic effect of MM-derived
exosomes was significantly abrogated by the
pre-treatment with anti-AREG mAb (Fig. 3a–d) suggest-
ing a direct effect of MM exosomes-derived AREG on
OC differentiation.
On the basis of these data, we investigated whether ex
vivo exosomes from MM patients deliver the EGFR lig-
and. Exosomes were isolated from BM aspirates of MM
patients. The vesicles were analyzed with DLS, showing
a clear distribution with peak at about 100 nm (Fig. 4a)
and with western blot for TSG101 (Fig. 4b). AREG was
enriched in the exosomes obtained from three out of
four patients, thus confirming the exosomal packaging
of the ligand. As observed with exosomes from MM1.S
cell line, we found that also patient-derived exosomes in-
crease the expression of SNAIL in pre-OCs, while the
presence of anti-AREG mAb abolished this effect
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(Fig. 4c). Similarly, the pro-osteoclastogenic effects of
exosomes obtained from MM patients were abrogated
by the pre-treatment with the anti-AREG mAb at
mRNA (Fig. 5a) and protein level as shown for MMP9
(Fig. 5b). Overall, these data indicate that the EGFR lig-
and AREG is packed into MM-derived exosomes and
directly involved in OC differentiation.
MM-derived exosomes are internalized into human BM
mesenchymal cells blocking osteogenic differentiation
and increasing the release of the pro-osteoclastogenic
cytokines through the activation of EGFR pathway
To further investigate the mechanism by which
AREG-enriched exosomes from MM cells are involved
in MM-induced alteration of bone remodeling, we eval-
uated the effect of exosomes on hTERT-MSCs. We dem-
onstrated that MM1.S-derived exosomes are internalized
into hTERT-MSCs independently by the neutralization
of AREG (Fig. 6a). Exosomes internalization by
hTERT-MSCs induced the activation of EGFR pathway
as demonstrated by the increase of the tyrosine kinase
receptor phosphorylation. EGFR activation was blocked
by the treatment of anti-AREG mAb (Fig. 6b).
Interestingly, under osteogenic conditions, the treat-
ment of hTERT-MSCs with MM1.S-derived exosomes
for 14 days reduces the mRNA levels of OB differenti-
ation markers (Fig. 7a). In addition to gene expression,
the ability of MM exosomes to inhibit ALP release was
evaluated at the protein level (Fig. 7b). OB differenti-
ation is characterized by the formation of mineralized
nodules. Therefore, we performed an in vitro
mineralization assay in order to functionally evaluate the
effect of MM exosomes on bone-like nodules deposited
by cells. As shown in Fig. 7c, 14 days of treatment of
hTERT-MSCs with MM1.S exosomes under osteogenic
conditions reduces the formation of mineralized nod-
ules. No differences were observed in exosomes-treated
MSCs maintained into an undifferentiated state. To fur-
ther confirm the observed exosomes-mediated inhibition
of OB differentiation, we performed a qRT-PCR of cells
treated with exosomes from the BM aspirates of MM
patients. Accordingly, 14day treatment of hTERT-MSCs
Fig. 1 a Box plot represents the median level of AREG expression of 11 monoclonal gammopathy of undetermined significance (MGUS), 133 MM
patients at diagnosis, and 9 plasma cell leukemia (PCL) (GSE16122). b Representative AFM image of MM1.S exosomes. c Total proteins were
extracted from MM1.S cells, MM1.S exosomes (exo), and exosome-deprived conditioned medium (cm-exo) and were subjected to western blot
analysis with an antibody against AREG
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under osteogenic conditions decreases OB differenti-
ation marker at the mRNA (Fig. 7d) and protein level
(Fig. 7e).
Finally, we found that the treatment of
hTERT-MSCs with exosomes increases the adhesion
of MM1.S cells to the mesenchymal monolayer and
that this effect is abrogated by the presence of the
anti-AREG mAb (Fig. 8a). Moreover, we found that
exosomes are able to reduce OPG mRNA and to in-
crease RANKL mRNA levels by hTERT-MSCs
(Fig. 8b). This effect was not inhibited by the
pre-treatment with blocking anti-AREG Ab (data not
shown) suggesting the lack of a direct effect of AREG
on RANKL/OPG expression.
Interestingly, a significant increase in the production of
the pro-osteoclastogenic cytokine IL8 by hTERT-MSCs
was observed at both mRNA (Fig. 8c) and protein level at
24 and 48 h (Fig. 8d). These effects were abrogated by the
pre-treatment with anti-AREG mAb (Fig. 8c, d).
To correlate the increased expression and secretion of
IL8 from exosomes-treated MSCs with the
exosomes-dependent increase of OC function, we
co-treated human CD14+ with (i) recombinant IL8
(rIL8) and (ii) with the conditioned medium of
Fig. 2 a Western blotting analysis of pEGFR and EGFR in whole lysates of RAW 264.7 cells incubated, for 6 days, with MM1.S derived exosomes
(50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml), with rhAREG (50 μg/ml) and rhRANKL (25 μg/ml). The histogram on the right represents
the ratio pEGFR/EGFR, based on densitometric analysis normalized versus GAPDH, used as loading control. b Evaluation by quantitative real-time
PCR of mRNA expression of SNAIL in RAW 264.7 incubated, for 3 and 6 days, with MM1.S-derived exosomes (50 μg/ml) treated or not with anti-
AREG mAb (50 μg/ml), rhRANKL (25 μg/ml), and rhAREG (50 μg/ml). Human PB CD14+ cells incubated for 6 days in osteoclastogenic medium
(rhRANKL 25 ng/ml and MCSF 25 ng/ml), with MM1.S derived exosomes (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml). *Exo vs
untreated (**p≤ 0.01; ***p≤ 0.001); #Exo+AREG mAb vs Exo (#p≤ 0.05)
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hTERT-MSCs treated with MM1.S exosomes, in the
presence or absence of the IL8 receptor (CXCR1–2) in-
hibitor, SB225002 (SB). The treatment with rIL8 induced
the expression of MMP9 and CTSK mRNA (Fig. 8e).
Consistently, the treatment with conditioned medium of
hTERT-MSCs pre-treated with MM exosomes increased
the expression of the osteoclastogenic markers. This ef-
fect was abrogated by the use of SB (Fig. 8e) thus con-
firming the role of IL8 released by MSCs after exosomes
stimulation, in the activation of OC differentiation.
Discussion
In this study, we focus on unveiling the molecular mech-
anism by which MM exosomes are able to affect OC
differentiation. We demonstrate that the EGFR ligand
AREG is packed into exosomes from MM cell line as
well as from the BM aspirates of patients and that its
presence is responsible for the exosome-induced osteo-
clastogenesis. The activation of the EGFR pathway has
been correlated to metastatic bone diseases and in par-
ticular to the increased bone resorption observed in
these tumors [28, 29]. In particular, in breast cancer,
Mercatali et al. showed that the crosstalk between MSCs
and cancer cells promoted osteoclastogenesis by stimu-
lating RANK and EGFR signaling pathways [30]. Fur-
thermore, EGFR deficiency impaired OC recruitment in
EGFR-deficient mice [31]. In MM, Mahtouk and col-
leagues showed that, among the EGFR ligands, AREG is
(See figure on previous page.)
Fig. 3 Evaluation by quantitative real-time PCR of mRNA expression of TRAP, CTSK, and MMP9 in a RAW 264.7 incubated, for 3 and 6 days, with
MM1.S-derived exosomes (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml), rhRANKL (25 μg/ml), and rhAREG (50 μg/ml). b Human PB
CD14+ cells incubated, for 6 days in osteoclastogenic medium (rhRANKL 25 ng/ml and MCSF 25 ng/m), with MM1.S derived exosomes (50 μg/ml)
treated or not with anti-AREG mAb (50 μg/ml). *Exo vs untreated (*p≤ 0.05; ***p≤ 0.001); #Exo+AREG mAb vs Exo (#p≤ 0.05). c MMP9 protein
level was measured by ELISA in the conditioned medium of Human PB CD14+ cells incubated, for 6 days in osteoclastogenic medium (rhRANKL
25 ng/ml and MCSF 25 ng/m), with MM1.S-derived exosomes (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml). *Exo vs untreated (*p≤
0.05); #Exo+AREG mAb vs Exo (#p≤ 0.05). d Trap staining of Human PB CD14+ seeded in 96 well plates in presence or absence of MM1.S-derived
exosomes (50 μg/ml) treated or not with mAb AREG and rhAREG anti-AREG mAb (50 μg/ml) for 6 days
Fig. 4 a MM patient exosomes size distribution was determined by DLS analysis. b Total proteins were extracted from exosomes isolated from
the BM plasma of MM patients and were subjected to western blot analysis with antibody against AREG and Tsg101. The table below indicates
the clinical information of the four MM patients analyzed. c Evaluation by quantitative real-time PCR of mRNA expression of SNAIL in Raw 264.7
cells incubated with exosomes from MM patients (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml). *Exo vs untreated (**p≤ 0.01); #Exo
+AREG mAb vs Exo (##p≤ 0.01)
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significantly over-expressed by MM cells as compared to
normal PCs and that it is able to stimulate cell growth
[32]. We have previously shown, consistent with others,
that cancer exosomes contain the EGFR ligands, includ-
ing AREG, suggesting that the EGFR system contributes
to the exosome-mediated communication within the
tumor microenvironment [33–35]. For example, Taverna
et al. demonstrated that non-small cell lung
cancer-derived exosomes, containing AREG, induce
EGFR pathway activation in pre-OCs leading to the in-
creased expression of RANKL [34]. Here, we found that
AREG is abundantly present in MM exosomes partially
explaining the previously observed exosome-mediated
increase of OC function in MM [16].
Since the presence of AREG is directly responsible for
the activation of OC function in exosome-treated
pre-OCs, we further assessed whether the presence of
the ligand in the exosomes was able to modulate MSC
phenotype and to activate OC formation indirectly
through MSCs. We found that the treatment of MSCs
with MM exosomes increased the release of IL8 in the
conditioned medium, while AREG depletion abrogated
the effect. Similarly, our recent data show that the lig-
and–receptor interaction between AREG produced by
leukemic cells, and EGFR by BM stromal cells, modu-
lates leukemic and stromal cells bidirectional crosstalk
[35]. In addition, in chronic myeloid leukemia model, we
have previously shown that AREG is involved in the acti-
vation of EGFR downstream signaling in mesenchymal
stromal cells leading to the expression and release of IL8
[27].
IL8 is responsible for the increased osteolysis observed
in metastatic bone disease [20] and that its release, fol-
lowing the interaction between MM cells and human
MSCs, contributed to in vitro OC formation [21]. Here,
we found that exosomes, through the activation of the
EGFR pathway, may also indirectly contribute to the in-
duction of osteoclastogenesis by promoting the release
of IL8 by MSCs; in fact, IL8-enriched conditioned
medium induces the expression of OC-specific markers
in human pre-OCs.
Based on our data showing that MM-derived exo-
somes block osteogenic differentiation of MSCs, it is
conceivable to hypotheses that MM exosomes contribute
to increase the number of undifferentiated MSCs and
consequently the production of pro-osteoclastogenic cy-
tokines as IL8 [21] and RANKL [36]. Accordingly, we
show that MM-derived exosomes increased the RANKL
mRNA expression and decreased that of OPG. Clearly,
this effect can be involved in the indirect
pro-osteoclastogenic effect of MM-derived exosomes.
However, anti-AREG mAb did not significantly affect
RANKL/OPG expression suggesting that the effects of
exosomes in reducing OPG mRNA and increase RANKL
is regulated by the exosome-mediated increase in cell
adhesion. Giuliani et al. demonstrated that the
cell-to-cell contact between myeloma cells and BM
MSCs by the integrin Very Late Antigen-4 (VLA-4)
Fig. 5 a Evaluation by quantitative real-time PCR of mRNA expression of TRAP, CTSK and MMP9 in Raw 264.7 cells incubated with exosomes from
MM patients (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml). b MMP9 protein level was measured in the conditioned medium of Raw
264.7 cells incubated, for 6 days, with exosomes from MM patients (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml), rhRANKL (25 μg/ml),
and rhAREG (50 μg/ml). *Exo vs untreated (*p≤ 0.05; **p≤ 0.01); #Exo+AREG mAb vs Exo (#p≤ 0.05; ##p≤ 0.01)
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affect the RANKL/OPG ratio a favor of RANKL [36].
We hypothesize that the changes in RANKL/OPG pro-
duction may be induced by the exosomes-induced in-
creased adhesion of MM cells to mesenchymal cells.
Moreover, exosomes may contribute to the block of
bone formation process through the activation of EGFR
pathway. In a recent study, Kumar and colleagues in vivo
demonstrated that exosomes from acute myeloid
leukemia modulate the BM niche; in particular, authors
showed that exosomes suppress osteogenic differenti-
ation of mesenchymal stromal progenitors [37]. Other
authors observed that MM cells-derived exosome
contain the lncRNA RUNX2-AS1 which is responsible
for the decreased expression of RUNX2 in MSCs, lead-
ing to the osteogenesis suppression [38]. Although in
this study authors identified one of the molecular inter-
actor of the exosome-mediated osteogenic inhibition,
further studies need to be conducted in order to
characterize MM exosome content and fully understand
how MM exosomes contribute to the uncoupled bone
remodeling by the inhibiting bone formation.
The observation that MM cell-derived exosomes in-
duced the activation of EGFR pathway in both OC pro-
genitors and in MSCs suggests the possibility to use
Fig. 6 a Analysis at confocal microscopy of hTERT-MSCs treated for 4 h with MM1.S exosomes pretreated or not with mAb AREG, compared with
untreated hTERT-MSCs (Ctrl). hTERT-MSCs were stained with phalloidin Alexa Fluor (green), nuclear counterstaining was performed using Hoescht
(blue), and exosomes were labeled with PKH26 (red); histogram shows fluorescence intensity expressed as ratio between a.u. and number of
hTERT-MSCs treated with MM1.S exosomes and MM1.S exosomes pretreated with mAb AREG. b Levels of EGFR and phospho-EGFR were
determined by FACS analysis in hTERT-MSCs after 48 h treatment with MM1.S exosomes pretreated or not with mAb AREG
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Fig. 7 a Evaluation by quantitative real-time PCR of mRNA expression of ALP, OCN, and COL1A1 in hTERT-MSC treated for 10 and 14 days with
MM1.S exosomes under undifferentiating medium (ctrl) or in osteogenic differentiation medium (diff). b ALP protein release was evaluated by
ELISA assay in the conditioned medium of hTERT-MSC treated for 14 days with MM1.S exosomes under undifferentiating medium (ctrl) or in
osteogenic differentiation medium (diff). c Quantification of in vitro osteoblast mineralization in the hTERT-MSC treated for 10 and 14 days with
MM1.S exosomes under undifferentiating medium (ctrl) or in osteogenic differentiation medium (diff) was evaluated using OsteoImage
Mineralization Assay Kit. Values are expressed as fluorescence units (RFU; 492 nm excitation/520 nm emission wavelengths). *Diff vs ctrl (*p≤ 0.05;
**p≤ 0.01; ***p≤ 0.001); #Diff+ Exo vs diff (#p≤ 0.05; ##p≤ 0.01). d Evaluation by quantitative real-time PCR of mRNA expression of ALP, OCN, and
COL1A1 in hTERT-MSC treated for 14 days with exosomes isolated from BM plasma of three MM patients in osteogenic differentiation medium
(diff). e ALP protein release was evaluated by ELISA assay in the conditioned medium of hTERT-MSC treated for 14 days with exosomes isolated
from BM plasma of three MM patients in osteogenic differentiation medium (diff). #Diff+ Exo vs diff (#p≤ 0.05; ##p ≤ 0.01; ###p ≤ 0.001)
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Fig. 8 (See legend on next page.)
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EGFR inhibitors such as erlotinib and gefitinib to impair
the cross talk between MM cells and the bone micro-
environment and potentially the development of bone
lesions. Consistently, it was reported that erlotinib in-
hibits osteolytic bone invasion of non-small lung cancer
[39] and that gefitinib inhibits the ability of MSC to in-
duce OC differentiation [40].
Conclusions
In conclusion, our data indicate that MM-derived exo-
somes could be responsible for the uncoupled bone re-
modeling increasing OC differentiation both directly and
indirectly through, at least in part, the release of IL8 by
MSCs (Additional file 2: Figure S2). Thus, AREG packed
into MM-derived exosomes may represent a potential
new player in MM-induced osteoclastogenesis.
Additional files
Additional file 1: Figure S1. Evaluation by quantitative Real Time PCR
of mRNA expression of AREG in HMCLs (A) and in MM1.S cells and
exosomes (B). (TIFF 2501 kb)
Additional file 2: Figure S2. Schematic representation of the role of
MM-exosomes in bone microenvironment. (TIF 3372 kb)
Abbreviations
AFM: Atomic force microscopy; AREG: Amphiregulin; BM: Bone marrow;
cDNA: Complementary DNA; CTSK: Cathepsin K; DLS: Dynamic light scatter;
EGFR: Epidermal growth factor receptor ligands; FBS: Fetal bovine serum;
HMCL: Human myeloma cell line; IL8: Interleukin-8; mAb: Monoclonal
antibody; MM: Multiple myeloma; MMP9: Matrix metallopeptidase 9;
MSCs: Mesenchymal stromal cells; OB: Osteoblast; OC: Osteoclast;
OPG: Osteoprotegerin; PBMC: Peripheral mononuclear cell; PC: Plasma cell;
RANKL: Nuclear factor kappa-Β ligand; TRAP: Tartrate-resistant acid
phosphatase
Funding
This work was supported by a grant from the Associazione Italiana per la
Ricerca sul Cancro (AIRC) to Riccardo Alessandro (grant n°18783). Nicola
Giuliani is supported by: IG2017 Grant (id. 20299) and the International
Myeloma Foundation under 2018 Brian D. Novis Senior Research Grant.
Stefania Raimondo is supported by a “FIRC” (Fondazione Italiana Ricerca sul
Cancro) fellowship (project n° 17927); she is also the recipient of the “Cecilia
Cioffrese, oncological diseases” award 2017, Fondazione Carlo Erba.
Availability of data and materials
Materials are available upon reasonable request.
Authors’ contributions
SR and RA designed the experiments; SR, LS, EV, NG, and RA wrote the
manuscript. SR, LS, and EV performed and analyzed the experiments; MP
helped in cell culture and exosome collection; DT supported manuscript
revision; MM and SR performed biophysical analysis. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
This study was conducted in full conformance with the principles of the
Declaration of Helsinki. All patients provided written informed consent. The
Institutional Review Board of the University of Parma (Italy) approved this
part of the study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interest exists.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Biopathology and Medical Biotechnologies (Di.Bi.Med.),
University of Palermo, Palermo, Italy. 2Department of Medicine and Surgery,
University of Parma, Parma, Italy. 3Institute of Biophysics (IBF), National
Research Council (CNR) of Italy, Palermo, Italy.
Received: 3 October 2018 Accepted: 25 December 2018
References
1. Raje N, Roodman GD. Advances in the biology and treatment of bone
disease in multiple myeloma. Clin Cancer Res. 2011;17(6):1278–86.
2. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, et al.
Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug
Targets. 2012;12(7):757–67.
3. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease:
pathophysiology of osteoblast inhibition. Blood. 2006;108(13):3992–6.
4. Hameed A, Brady JJ, Dowling P, Clynes M, O’Gorman P. Bone disease in
multiple myeloma: pathophysiology and management. Cancer Growth
Metastasis. 2014;7:33–42.
5. Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA.
Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
Blood Cancer J. 2018;8(1):7.
6. Galson DL, D’Souza S, Osteoclasts RGD. Potential target for blocking
microenvironmental support of myeloma. In: Munshi NC, Anderson KC,
editors. Advances in biology and therapy of multiple myeloma: volume 1:
basic science. New York: Springer New York; 2013. p. 169–85.
7. Reagan MR, Liaw L, Rosen CJ, Ghobrial IM. Dynamic interplay between bone
and multiple myeloma: emerging roles of the osteoblast. Bone. 2015 Jun;75:
161–9.
8. Fu J, Wang P, Zhang X, Ju S, Li J, Li B, et al. Myeloma cells inhibit
osteogenic differentiation of mesenchymal stem cells and kill osteoblasts
via TRAIL-induced apoptosis. Arch Med Sci. 2010;6(4):496–504.
(See figure on previous page.)
Fig. 8 a Adhesion assay of MM1.S exo on hTERT-MSCs: pre-treatment of hTERT-MSCs cells with MM1.S exo for 48 h increases MM1.S cell adhesion
to mesenchymal cells. Treatment with exosomes pretreated with anti-AREG mAb reduces this effect. Right panel: a representative phase contrast
micrograph showing the adhesion of MM1.S cells to exosome-treated hTERT-MSCs monolayer. b Evaluation by quantitative Real Time PCR of
mRNA expression of OPG and RANKL in hTERT-MSC treated for 14 days with MM1.S exosomes in osteogenic differentiation medium (diff) (*p≤
0.05; **p≤ 0.01). c IL8 mRNA expression was evaluated by real-time PCR in hTERT-MSCs treated for 24 or 48 h with MM1.S exosomes pretreated or
not with anti-AREG mAb for 24 and 48 h. d IL8 protein release was evaluated by ELISA assay in the conditioned medium of hTERT-MSCs
monolayer after 48 h treatment with MM1.S exosomes pretreated or not with anti-AREG mAb. *Exo vs untreated (*p≤ 0.05; **p≤ 0.01; ***p≤
0.001); #Exo+AREG mAb vs Exo (#p≤ 0.05; ##p≤ 0.01). e Evaluation by quantitative real-time PCR of mRNA expression of CTSK and MMP9 in CD14+
monocytes untreated or treated for 6 days with rIL8, with the conditioned medium of BMMSC cells treated with MM1.S exosomes with or
without SB225002 (*p≤ 0.05; **p≤ 0.01)
Raimondo et al. Journal of Hematology & Oncology            (2019) 12:2 Page 14 of 15
9. Corrado C, Raimondo S, Chiesi A, Ciccia F, De Leo G, Alessandro R.
Exosomes as intercellular signaling organelles involved in health and
disease: basic science and clinical applications. Int J Mol Sci. 2013;14(3):
5338–66.
10. Raimondo S, Corrado C, Raimondi L, De Leo G, Alessandro R. Role of
extracellular vesicles in hematological malignancies. Biomed Res Int. 2015;
2015:821613.
11. Arendt BK, Walters DK, Wu X, Tschumper RC, Jelinek DF. Multiple myeloma
dell-derived microvesicles are enriched in CD147 expression and enhance
tumor cell proliferation. Oncotarget. 2014;5(14):5686–99.
12. Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots R, et al.
Extracellular vesicle cross-talk in the bone marrow microenvironment:
implications in multiple myeloma. Oncotarget. 2016;7(25):38927–45.
13. Liu Y, Zhu XJ, Zeng C, Wu PH, Wang HX, Chen ZC, et al. Microvesicles
secreted from human multiple myeloma cells promote angiogenesis. Acta
Pharmacol Sin. 2014;35(2):230–8.
14. Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH.
Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances
angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014;124(25):3748–57.
15. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. BM
mesenchymal stromal cell-derived exosomes facilitate multiple myeloma
progression. J Clin Invest. 2013;123(4):1542–55.
16. Raimondi L, De Luca A, Amodio N, Manno M, Raccosta S, Taverna S, et al.
Involvement of multiple myeloma cell-derived exosomes in osteoclast
differentiation. Oncotarget. 2015;6(15):13772–89.
17. Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, et al. Epidermal growth factor
receptor regulates osteoclast differentiation and survival through cross-
talking with RANK signaling. J Cell Physiol. 2008;217(2):409–22.
18. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L. EGF-like ligands stimulate
osteoclastogenesis by regulating expression of osteoclast regulatory factors
by osteoblasts: implications for osteolytic bone metastases. J Biol Chem.
2007;282(37):26656–64.
19. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, et al. Interleukin-
8 is associated with proliferation, migration, angiogenesis and
chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J
Cancer. 2011;128(9):2038–49.
20. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8
stimulation of osteoclastogenesis and bone resorption is a mechanism for
the increased osteolysis of metastatic bone disease. Bone. 2003;33(1):28–37.
21. Herrero AB, Garcia-Gomez A, Garayoa M, Corchete LA, Hernandez JM, San
Miguel J, et al. Effects of IL-8 up-regulation on cell survival and
osteoclastogenesis in multiple myeloma. Am J Pathol. 2016;186(8):2171–82.
22. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, et al. A SNP
microarray and FISH-based procedure to detect allelic imbalances in
multiple myeloma: an integrated genomics approach reveals a wide gene
dosage effect. Genes Chromosomes Cancer. 2009;48(7):603–14.
23. Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, et al. The
reconstruction of transcriptional networks reveals critical genes with
implications for clinical outcome of multiple myeloma. Clin Cancer Res.
2011;17(23):7402–12.
24. Costa F, Toscani D, Chillemi A, Quarona V, Bolzoni M, Marchica V, et al. Expression
of CD38 in myeloma bone niche: a rational basis for the use of anti-CD38
immunotherapy to inhibit osteoclast formation. Oncotarget. 2017;8(34):56598–611.
25. Raimondo S, Saieva L, Corrado C, Fontana S, Flugy A, Rizzo A, et al. Chronic
myeloid leukemia-derived exosomes promote tumor growth through an
autocrine mechanism. Cell Commun Signal. 2015;13:8.
26. Noto R, Santangelo MG, Ricagno S, Mangione MR, Levantino M, Pezzullo M,
et al. The tempered polymerization of human neuroserpin. PLoS One. 2012;
7(3):e32444.
27. Corrado C, Raimondo S, Saieva L, Flugy AM, De Leo G, Alessandro R.
Exosome-mediated crosstalk between chronic myelogenous leukemia cells
and human bone marrow stromal cells triggers an interleukin 8-dependent
survival of leukemia cells. Cancer Lett. 2014;348(1–2):71–6.
28. Hou CH, Lin FL, Tong KB, Hou SM, Liu JF. Transforming growth factor alpha
promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling
pathway. Biochem Pharmacol. 2014;89(4):453–63.
29. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, et
al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol.
2008;214(3):559–67.
30. Mercatali L, La Manna F, Miserocchi G, Liverani C, De Vita A, Spadazzi C, et
al. Tumor-stroma crosstalk in bone tissue: the osteoclastogenic potential of
a breast cancer cell line in a co-culture system and the role of EGFR
inhibition. Int J Mol Sci. 2017;18(8):1655. https://doi.org/10.3390/
ijms18081655.
31. Wang K, Yamamoto H, Chin JR, Werb Z, Vu TH. Epidermal growth factor
receptor-deficient mice have delayed primary endochondral ossification
because of defective osteoclast recruitment. J Biol Chem. 2004;279(51):
53848–56.
32. Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, Moreaux J, et al.
Expression of EGF-family receptors and amphiregulin in multiple myeloma.
Amphiregulin is a growth factor for myeloma cells. Oncogene. 2005;24(21):
3512–24.
33. Higginbotham JN, Demory Beckler M, Gephart JD, Franklin JL, Bogatcheva
G, Kremers GJ, et al. Amphiregulin exosomes increase cancer cell invasion.
Curr Biol. 2011;21(9):779–86.
34. Taverna S, Pucci M, Giallombardo M, Di Bella MA, Santarpia M, Reclusa P, et al.
Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation
through the activation of EGFR pathway. Sci Rep. 2017;7(1):3170.
35. Corrado C, Saieva L, Raimondo S, Santoro A, De Leo G, Alessandro R.
Chronic myelogenous leukaemia exosomes modulate bone marrow
microenvironment through activation of epidermal growth factor receptor.
J Cell Mol Med. 2016;20(10):1829–39.
36. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce
imbalance in the osteoprotegerin/osteoprotegerin ligand system in the
human bone marrow environment. Blood. 2001;98(13):3527–33.
37. Kumar B, Garcia M, Weng L, Jung X, Murakami JL, Hu X, et al. Acute myeloid
leukemia transforms the bone marrow niche into a leukemia-permissive
microenvironment through exosome secretion. Leukemia. 2017.
38. Li B, Xu H, Han H, Song S, Zhang X, Ouyang L, et al. Exosome-mediated
transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes
to osteogenesis. Oncogene. 2018;37(41):5508-19. https://doi.org/10.1038/
s41388-018-0359-0.
39. Furugaki K, Moriya Y, Iwai T, Yorozu K, Yanagisawa M, Kondoh K, et al.
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung
cancer cell line NCI-H292. Clin Exp Metastasis. 2011;28(7):649–59.
40. Normanno N, De Luca A, Aldinucci D, Maiello MR, Mancino M, D'Antonio A,
et al. Gefitinib inhibits the ability of human bone marrow stromal cells to
induce osteoclast differentiation: implications for the pathogenesis and
treatment of bone metastasis. Endocr Relat Cancer. 2005;12(2):471–82.
Raimondo et al. Journal of Hematology & Oncology            (2019) 12:2 Page 15 of 15
